Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile

AHT-102, a novel Fab-like bispecific antibody, achieves an optimized therapeutic balance through its low-affinity CD3 arm and Fc-free format. It demonstrates significant anti-tumor efficacy and exceptional targeting specificity while avoiding systemic immunotoxicity typically associated with CD3-targeting agents. These findings provide a robust scientific rationale for the clinical translation of AHT-102 in patients with CLDN18.2-positive cancers.